TCRT MEXC RealStocks
Own real TCRT shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-18 07:43:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Alaunos Therapeutics, Inc. (TCRT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.66, with a market capitalization of $4.06M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.72 to $4.50. This page covers its latest market performance, valuation, price trends and company information.
$4.06M | |
$1.53 | |
$1.66 | |
$1.51 | |
$1.60 | |
57.05K | |
7.67M | |
-- | |
$4.50 | |
$0.72 | |
-- | |
-- |
Alaunos Therapeutics, Inc. (TCRT) last closed at $1.66 as of 2026-11-18 00:59:00, up 2.50% ($0.04) from the previous close of $1.60.
During the latest regular trading session, TCRT traded between $1.51 and $1.66, with a volume of 57.05K shares. The closing price was near the upper end and near the lower end of its 52-week range.
Over the past seven days, Alaunos Therapeutics, Inc. (TCRT) moved from $1.67 to $1.66, representing a decline of 0.90% ($0.01).
The stock traded between $1.51 and $1.86 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 78.24 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 24.8%
TCRT is currently trading at $1.66, placing it 24.8% of the way from its 52-week low of $0.72 to its 52-week high of $4.50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 1 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Alaunos Therapeutics, Inc. (TCRT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to TCRT, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between TCRT shares and USD.
TCRT Shares to USD
1.00 TCRT shares = 1.655 USD
Calculations are estimates based on the latest available price and are for reference only.